Jubilant Pharmova to Invest $300 Million in US to Double Sterile Injectable Capacity by FY28

’s subsidiary, Jubilant HollisterStier LLC, has announced a $300 million investment by FY28 to double its sterile injectable manufacturing capacity in the US. The expansion, led by the addition of a new $132 million sterile fill-and-finish line at its Spokane, Washington facility, marks the first of two phases. Once completed, the company’s annual vial production is expected to rise from 50 million to 100 million units. Backed by a $150 million US government grant, this move aligns with growing demand for onshore pharmaceutical manufacturing and a global shortfall of nearly 700 million sterile vials, as identified by McKinsey. The project strengthens Jubilant’s position as a leading CDMO in sterile injectables, meeting rising US healthcare needs while enhancing medicine security and supply resilience. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.